Plain-English translation of NCT07068490 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Coronary Artery Disease research guide →This trial is testing a newer stomach protection medication called potassium competitive acid blockers (P-CAB) in patients who have recently had a stent placed in their heart arteries and are taking dual blood thinners. The medication is designed to protect the stomach lining from irritation that can sometimes occur with these blood thinners. Researchers want to know if using this newer medication routinely is safer and more effective than using older stomach protection drugs only when a patient has a high risk of stomach bleeding.
When people receive heart stents, they must take two blood-thinning medications together for several months, which can sometimes irritate or damage the stomach lining. Current guidelines recommend giving stomach protection medication only to patients at high risk of stomach bleeding, but researchers want to understand whether protecting everyone's stomach with this newer medication might prevent more problems overall.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would be assigned to one of two groups: either take the newer stomach protection medication routinely, or follow current guidelines (taking stomach protection only if you have a high risk of stomach bleeding). The study will track a very large group of patients — up to 100,000 people — using medical records and data that already exist, rather than requiring frequent clinic visits. Researchers will monitor you for any stomach problems and other health events over time.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
South Korea